Neoplasia/BPH

	Combining VEGFR tyrosine kinase inhibitors and PD-1/PD-L1 inhibitors versus VEGFR tyrosine kinase inhibitors monotherapy in renal cell carcinoma: a target trial emulation. medRxiv Shi D, Li X, Chen Y, Chen Y, Song Q, Su J. PMID: 42428070 [PubMed - in process]
	A genome-wide Mendelian randomization study focusing on endoplasmic reticulum stress reveals novel genetic markers for renal cell carcinoma. Oncol Lett Gao B, Li Z, Shi J, Shen J. PMID: 42427927 [PubMed - in process]
	Integrating MRI-based tumour staging within the TNM classification system in modern prostate cancer management. Insights Imaging Agrotis G, Purysko A, Padhani A, Jäderling F, Villeirs G, Withey SJ, de Rooij M, Barrett T, Schoots IG. PMID: 42426432 [PubMed]
	Prognostic factors and the role of pelvic lymph node dissection in oligometastatic prostate cancer: a multicenter exploratory study. Surg Endosc Hu J, Yuan Y, Zou X, Liu X, Liu W, Dong Y, Wang B, Fu B. PMID: 42426390 [PubMed - as supplied by publisher]
	Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer. Nat Rev Urol Fletcher SA, Pickersgill NA, Osorio JC, McHugh DJ, Nagar H, Kole T, Janopaul-Naylor J, Lacuna K, Eastham JA, Touijer KA, Fainberg JS, Scher HI, Ehdaie B, Dallos MC, Gaffney CD. PMID: 42426291 [PubMed - as supplied by publisher]
	Re: Murthy V, Maitre P, Pal M, et al. Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-invasive Bladder Cancer. J Clin Oncol. In press. http://dx.doi.org/10.1200/JCO-25-02093. Eur Urol Miao J, Yi X. PMID: 42425857 [PubMed - as supplied by publisher]
	[How to prevent and manage PARP inhibitor-related hematological toxicities in prostate cancer?]. Bull Cancer Cassuto O, Schmitt A, Helissey C, Gobert A, Mathieu R, Bouteleux C, Mourey L, Jovenin N, Joly F. PMID: 42425824 [PubMed - as supplied by publisher]
	Natural History of Patients Eligible for PROTEUS Diagnosed with Prostate Cancer and Treated with Radical Prostatectomy Without Perioperative Systemic Treatment. Eur Urol Focus Hoeh B, Mazzucato G, Tennstedt P, Ekrutt J, Preisser F, Budäus L, Maurer T, Graefen M, Tilki D, Mandel P, Steuber T. PMID: 42425812 [PubMed - as supplied by publisher]
	Assessing tumor hypoxia in prostate cancer using intravoxel incoherent motion: a hypothesis-generating study. Clin Radiol Alagbe OA, Pascoal AM, Chahud F, Colli LM, Borges Dos Reis R, Muglia VF. PMID: 42424761 [PubMed - as supplied by publisher]
	The significance of vascular endothelial growth factor and systemic inflammatory reaction in bladder cancer patients. Cytokine Strojny Z, Kanikowska D, Kanikowska A, Tomczak Z, Sikora W, Sato M, Strojny M, , Deja T, Br, Korybalska K. PMID: 42424711 [PubMed - as supplied by publisher]
	Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world study. Jpn J Clin Oncol Tsuru I, Taguchi S, Tanaka R, Kawai T, Kaneko T, Nakamura Y, Miyauchi Y, Hoshina H, Obinata D, Koshiba M, Shiozaki M, Takahashi J, Kano M, Naito A, Suda S, Noda M, Sugiyama N, Tanaka T, Uemura Y, Miyakawa J, Kamei J, Kakutani S, Niimi A, Yamada Y, Sato Y, Yamada Y, Nishimatsu H, Murata T, Takahashi S, Takada T, Akiyama Y, Takahashi S, Fujimura T, Fukuhara H, Nakagawa T, Kume H. PMID: 42424546 [PubMed - as supplied by publisher]
	Platinum-based chemotherapy in metastatic castration-resistant prostate cancer: a narrative review and dual stratification framework based on HRR genotype and aggressive-variant/neuroendocrine phenotype. Int Urol Nephrol Chen H, Wang Y, Ding Y, Qu M, Gao X. PMID: 42423955 [PubMed - as supplied by publisher]
	Outcomes of Neoadjuvant Radiotherapy Followed by Robotic Radical Prostatectomy in High-Risk Locally Advanced Prostate Cancer: A Prospective Pilot Study. Ann Surg Oncol Tseng CS, Chang CK, Li HJ, Liu YT, Huang SW, Huang CY, Cheng JC. PMID: 42423939 [PubMed - as supplied by publisher]
	Association Between Psoriasis and Prostate Cancer Risk in Men: A Retrospective Cohort Study. J Epidemiol Glob Health Lai SW, Liao KF. PMID: 42423818 [PubMed - as supplied by publisher]
	[Geriatric assessments and their practical application in uro-oncology : How do we decide on prostate cancer treatment in an age-appropriate way?]. Urologie Fiebig C, Manseck A, Stein J, Piotrowski A, Fröhner M, Umbehr M, Butea-Bocu M, Wiedemann A. PMID: 42423720 [PubMed - as supplied by publisher]
	Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum. J Urol Shore ND, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Sridharan S, Brasso K, Woo HH, Caamaño AG, Saranchuk JW, Nordquist LT, Ferreira U, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ. PMID: 42423152 [PubMed - in process]
	A retrospective observational analysis of the global burden of smoking-attributable prostate, bladder, and kidney cancers among adults aged 40 years and older: Based on the global burden of disease study 2021 with projections to 2045. Sci Prog Chen N, Cai J, Feng J, He Y, Xu D. PMID: 42423065 [PubMed - indexed for MEDLINE]
	Overview of clear cell renal cell carcinoma: from mechanisms to clinical. Front Med (Lausanne) Yang H, Zhang X, Ji Q, Sheng X. PMID: 42422841 [PubMed]
	Late Renal Cell Carcinoma Metastasis Mimicking an Arteriovenous Malformation in the Parotid and Masseter Region: A Diagnostic Pitfall. Cureus Huerta Diaz LA, Lopez Alanis BA, Ortiz Villeda FE, Treviño Lozano MA, Muñoz-Maldonado GE. PMID: 42422606 [PubMed]
	Magnetic Resonance Imaging-based Prostate Cancer Diagnosis Using Principal Component Analysis and Machine Learning Algorithms. J Med Phys Samta N, Sureka CS, Sarasanandarajah S, Jeevanram RK. PMID: 42422134 [PubMed]

Articles 1 - 20 / 189597

Page 1 of 9480



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy